Anti-TNF therapy: Where have we got to in 2005?
- 31 December 2005
- journal article
- review article
- Published by Elsevier BV in Journal of Autoimmunity
- Vol. 25, 26-28
- https://doi.org/10.1016/j.jaut.2005.09.006
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonistsAnnals Of The Rheumatic Diseases, 2005
- Anti B cell therapy (rituximab) in the treatment of autoimmune diseasesCurrent Opinion in Pharmacology, 2004
- Treatment of rheumatoid arthritis with humanized anti–interleukin‐6 receptor antibody: A multicenter, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2004
- Targeting tumor necrosis factor-α in inflammatory bowel diseaseCurrent Opinion in Gastroenterology, 2003
- Bruton's Tyrosine Kinase Is Required For Lipopolysaccharide-induced Tumor Necrosis Factor α ProductionThe Journal of Experimental Medicine, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?Annual Review of Immunology, 2001
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral ProteinsScience, 1990
- Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of EndotoxinScience, 1985